

Reference number
1790-H

SPECIALTY QUANTITY LIMIT PROGRAM

CAPRELSA (vandetanib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of medullary thyroid cancer, follicular, Hurthle, and papillary thyroid cancer, and non-small cell lung cancer with RET gene arrangements fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Caprelsa 100 mg tablets	60 per 30 days	Standard dosing: 300 mg per day
Caprelsa 300 mg tablets	30 per 30 days	Severe toxicities, QTc interval prolongation: 200 mg (two 100 mg tablets) or 100 mg per day Renal impairment: 200 mg per day

III. REFERENCES

1. Caprelsa [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; December 2016.